Related Experiment Video
Updated: Jun 20, 2026
04:09
Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
Published on: June 13, 2025
[SSRI - treatment and bleeding. What risks do we take?].
T Strubel1, A Birkhofer, G Mössmer
1Klinikum rechts der Isar, Klinik und Poliklinik für Psychiatrie und Psychotherapie der TU München, Ismaningerstrasse 22, 81675, München, Deutschland. strubel@lrz.tu-muenchen.de
Der Nervenarzt
|August 21, 2009
Summary
Selective serotonin reuptake inhibitors (SSRI) increase gastrointestinal bleeding risk, especially with NSAIDs. Doctors must inform patients and monitor high-risk individuals closely for safer antidepressant use.
Area of Science:
- Pharmacology
- Clinical Medicine
- Gastroenterology
Context:
- Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed antidepressants.
- Gastrointestinal bleeding is a known adverse effect associated with SSRI use.
- Concurrent use of NSAIDs, antiplatelet agents, or presence of bleeding disorders exacerbates this risk.
Purpose:
- To review the literature on SSRI-associated bleeding risks.
- To provide clinical recommendations for managing these risks.
- To highlight the importance of patient communication and risk stratification.
Summary:
- SSRIs significantly increase the risk of gastrointestinal bleeding.
- Combining SSRIs with NSAIDs further elevates this risk.
- Bleeding events outside the GI tract, such as intracerebral hemorrhages, are not increased by SSRIs, even with anticoagulants like coumarin or aspirin.
- Close patient monitoring, use of low-interaction SSRIs, and consideration of gastroprotection are recommended for high-risk patients.
Impact:
- Enhances clinician awareness of SSRI-related bleeding hazards.
- Promotes safer prescribing practices for antidepressants.
- Aims to reduce the incidence of SSRI-induced gastrointestinal bleeding events.
Related Concept Videos
01:17Hemorrhagic Stroke l: Introduction
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...